Argenx publishes ADHERE Study in Lancet Neurology

Argenx announced publication in The Lancet Neurology of the ADHERE Study, the largest clinical trial to date in chronic inflammatory demyelinating polyneuropathy, or CIDP. CIDP is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system. This is the first time the ADHERE Study has been published in a peer-reviewed medical journal. ADHERE met its primary endpoint demonstrating a 61% reduction in the risk of relapse versus placebo; 69% of patients treated with Vyvgart Hytrulo, regardless of prior treatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength and 99% of trial participants elected to participate in the ADHERE open-label extension. Vyvgart Hytrulo was well-tolerated and safety results were consistent with the known safety profile of Vyvgart in previous clinical studies and real-world use. Vyvgart Hytrulo reduced the risk of relapse by 61% as assessed by aINCAT deterioration versus placebo. Vyvgart Hytrulo reduced the risk of CIDP disease progression based on time-to-first 4-point decrease in I-RODS score compared with Stage B baseline. In Stage A, time to first improvement on aINCAT, I-RODS, or grip strength scores among the 25th percentile of patients was 9.0 days after the first dose of Vyvgart Hytrulo; the median estimate was 22 days. In June, the FDA approved Vyvgart Hytrulo for the treatment of adult patients with CIDP. Vyvgart Hytrulo is also approved for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.